CA1152493A - Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications - Google Patents

Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications

Info

Publication number
CA1152493A
CA1152493A CA000365671A CA365671A CA1152493A CA 1152493 A CA1152493 A CA 1152493A CA 000365671 A CA000365671 A CA 000365671A CA 365671 A CA365671 A CA 365671A CA 1152493 A CA1152493 A CA 1152493A
Authority
CA
Canada
Prior art keywords
thiolation
groups
agent
fragment
iib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000365671A
Other languages
English (en)
French (fr)
Inventor
Bernard Bizzini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Application granted granted Critical
Publication of CA1152493A publication Critical patent/CA1152493A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000365671A 1979-11-28 1980-11-27 Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications Expired CA1152493A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7929289A FR2470773B1 (https=) 1979-11-28 1979-11-28
FR7929.289 1979-11-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA000425262A Division CA1178949A (en) 1979-11-28 1983-04-05 Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications

Publications (1)

Publication Number Publication Date
CA1152493A true CA1152493A (en) 1983-08-23

Family

ID=9232177

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000365671A Expired CA1152493A (en) 1979-11-28 1980-11-27 Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications

Country Status (5)

Country Link
EP (2) EP0030496B1 (https=)
JP (1) JPS5690097A (https=)
CA (1) CA1152493A (https=)
ES (2) ES8202831A1 (https=)
FR (1) FR2470773B1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435792B2 (en) 1997-08-14 2008-10-14 Institut Pasteur Hybrid proteins that migrate retrogradely and transynaptically into the CNS
US7923015B2 (en) 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
SE8102193L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
WO1992019646A1 (en) * 1991-05-03 1992-11-12 The Rockefeller University Analog of endothelial leukocyte adhesion molecule (elam)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3171831A (en) * 1961-02-14 1965-03-02 Schwarz Biores Inc Thiolation of proteins by reaction with homocysteine thiolactone in the presence of tertiary amine
DE1617880A1 (de) * 1966-10-06 1971-07-22 Karl Dr Med Theurer Verfahren zur Gewinnung von organotropen,bioaktiven Wirkstoffen,insbesondere von Arzneimitteln
FR2270891A2 (en) * 1974-05-15 1975-12-12 Anvar Vaccines by glutaraldehyde detoxification - especially multivalent vaccines e.g. against tetanus and diphtheria
IN140168B (https=) * 1974-10-14 1976-09-25 All India Inst Med
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
JPS5341420A (en) * 1976-09-29 1978-04-14 Mochida Pharm Co Ltd Immunochemically measuring methoa of hapten
SE427505B (sv) * 1977-03-04 1983-04-11 Pharmacia Diagnostics Ab Reagens till anvendning vid immunkemiska bestemningsmetoder
US4234561A (en) * 1978-02-06 1980-11-18 Research Corporation Antigen for early pregnancy test and contraceptive vaccine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435792B2 (en) 1997-08-14 2008-10-14 Institut Pasteur Hybrid proteins that migrate retrogradely and transynaptically into the CNS
US7923015B2 (en) 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport

Also Published As

Publication number Publication date
FR2470773B1 (https=) 1983-01-28
ES497182A0 (es) 1982-03-01
ES8400460A1 (es) 1983-10-16
EP0065320A1 (fr) 1982-11-24
EP0065320B1 (fr) 1985-04-03
ES8202831A1 (es) 1982-03-01
ES507625A0 (es) 1983-10-16
EP0030496A1 (fr) 1981-06-17
EP0030496B1 (fr) 1983-07-13
FR2470773A1 (https=) 1981-06-12
JPS5690097A (en) 1981-07-21

Similar Documents

Publication Publication Date Title
US4479940A (en) Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications
US4594336A (en) Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application
US4340535A (en) Cytotoxic products formed by covalent bonding of the A chain of ricin with an antibody and the process for their preparation and use
US4179337A (en) Non-immunogenic polypeptides
Brinkley A brief survey of methods for preparing protein conjugates with dyes, haptens and crosslinking reagents
JP2942356B2 (ja) 毒素および薬剤を含む治療用複合体
KR910000029B1 (ko) 효소와 항체의 공유 결합에 의해 결합된 접합체의 제조방법
EP0055115B1 (en) Cytotoxic protein hybrid and process for the preparation thereof
EP0112720B1 (en) Conjugate having cytotoxicity and process for the preparation thereof
CA1183775A (en) Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications
CA1152493A (en) Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications
Setlow et al. Localization of low-molecular-weight basic proteins in Bacillus megaterium spores by cross-linking with ultraviolet light
IE42760B1 (en) Derivatives of the tetanus toxin, process for their preparation and agents containing them
AU602320B2 (en) Ribosome inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged-action immunotoxins containing such a glycoprotein
US4843147A (en) Anhydrous enhanced coupling of proteins
CA1178949A (en) Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications
CA1264667A (en) Process for the preparation of prolonged-action immunotoxins containing a glycopeptide constituent which inactivates ribosomes, modified on its polysaccharide units
JPH0582400B2 (https=)
US4835258A (en) Conjugation of aromatic amines or nitro-containing compounds with proteins or polypeptides by photoirradiation of the azide derivatives with ultraviolet light in order to produce antibodies against the haptens
Paik et al. Interposition of different chemical linkages between antibody and 111In-DTPA to accelerate clearance from non-target organs and blood
Jones et al. The use of maleimidocaproyloxysuccinimide to prepare malarial peptide carrier immunogens Immunogenicity of the linking region
Wan et al. Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor
Husain et al. Fc site-specific labeling of immunoglobulins with calf intestinal alkaline phosphatase
Bizzini et al. Preparation of conjugates using two tetanus toxin derived fragments: their binding to gangliosides and isolated synaptic membranes and their immunological properties
Hoffmann et al. Overproduction of the proFhuA outer membrane receptor protein of Escherichia coli K-12: isolation, properties, and immunocytochemical localization at the inner side of the cytoplasmic membrane

Legal Events

Date Code Title Description
MKEX Expiry